Connect with us

Press Release

A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today

Published

on

SHENZHEN, CHINAOn the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8).

Description: 敲锣时刻

Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy.

At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast Asia and the Middle East. This move not only facilitates CMS’s comprehensive and sustainable development in Asia-Pacific markets, but also enhances our international influence and competitiveness, enabling us to serve broader patient populations with high-quality and affordable medication options.”      

 

New CMS  New Ascent

Over the 33-year journey, CMS has continuously challenged and surpassed itself through three strategic transformations to adapt to the external ecosystem: evolving from “China’s largest CSO” (1992-2010), to “transition from CSO to Pharma” (2010-2018), and since 2018, gradually establishing three core strategies of “Innovation-driven, Specialty Breakthroughs and Industrial Internationalization” to promote the upgrading and iteration of “New CMS”, accumulating momentum for takeoff.

 

CMS has established a comprehensive pharmaceutical product lifecycle management system, covering every stage from target identification to clinical development, product registration and commercialization. The Group focuses on FIC (First-in-Class) and BIC (Best-in-Class)  innovative products, and has meticulously built a pipeline of approximately 40 innovative products with differentiated advantages, among which 5 innovative drugs have been approved and successfully commercialized in China. With the impact of VBP (Volume-Based Procurement) mostly cleared, CMS has entered a new cycle of high-quality and sustainable development driven by exclusive and innovative drugs.

 

In specialty fields, the Group focuses on cardio-cerebrovascular, gastroenterology, ophthalmology and skin health, continuously deepening product portfolios and expert networks. Notably, the Group’s skin health business “DERMAVON” has emerged as a leader in its sector and is proposed for an independent listing on the Main Board of the Hong Kong Stock Exchange.

 

 

A Pioneer in Industrial Internationalization  Synergized Development Across the Entire “R&D, Manufacturing and Commercialization” Value Chain

Since 2022, CMS has initiated its “Industrial Internationalization” strategy by extending the Group’s advantages and resources from the Chinese market to emerging markets. Utilizing Singapore as the strategic pivot, the Group has established a localized cluster comprising CMS R&D, PharmaGend, and Rxilient, achieving synergized development across the entire pharmaceutical value chain from R&D to production and commercialization, driving deeper and broader market expansion across the Asia-Pacific region.

 

Internationalization of the Commercialization System: Rxilient serves as a platform for drug introduction, R&D and commercialization, operated by a professional and experienced localized team. Headquartered in Singapore, its business has expanded to 14 countries and regions including Malaysia, Thailand, Vietnam, the Philippines, Indonesia, and the Middle East, helping partners from China, the US, and Europe bring innovative drugs to emerging markets while introducing more high-quality and affordable treatment options to local markets. As of now, Rxilient has cumulatively submitted marketing applications for nearly 20 drugs and medical devices across Southeast Asia, the Middle East, Hong Kong, Macao and Taiwan, covering therapeutic areas such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system.

 

Internationalization of the Production System: PharmaGend, as an international CDMO platform based in Singapore, has a site spanning 30,000 square meters and is capable of manufacturing dosage forms such as tablets and capsules, with plans to expand production lines for injections, ointments, and nasal sprays. The factory has been certified by international authorities such as the FDA and the HSA, demonstrating its high-standard pharmaceutical manufacturing capabilities for global export .

 

Structural factors including large population bases, healthcare insurance expansion and rising chronic disease burdens are transforming Southeast Asia, the Middle East and other emerging markets into new growth engines for the global pharmaceutical industry. Leveraging its integrated ecosystem, CMS is forming a novel model for Chinese pharmaceutical globalization – not only enabling incremental market conversion for its own products in emerging markets, but also providing global partners with a reliable one-stop solution, thereby generating additional growth momentum for the Group.

 

Looking ahead, CMS will continue advancing its three core strategies to build the long-term value system of “New CMS”. By persistently enhancing accessibility to pharmaceutical innovation, CMS aims to benefit more patients, achieve sustainable healthy development, and deliver substantial value returns to investors.

 

 

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Groups market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

DLMSPV LLC and Michael Hartnett Helping Global Investors Identify Quality Assets through DSLAI and DLMSPVAI Frameworks

Published

on

In the complex world of global finance, the ability to distinguish between noise and genuine opportunity has become the defining factor separating consistent success from uncertainty. As global markets evolve under the influence of AI, digitization, and capital redistribution, investors face an overwhelming array of data and decisions. DLM SPV LLC, under the strategic guidance of renowned analyst and educator Michael Hartnett, is pioneering a data-driven approach that simplifies this challenge — integrating artificial intelligence and behavioral modeling through its proprietary systems, DSLAI, DLMSPV, and DLMSPVAI.

The Modern Investor’s Dilemma

The financial markets of 2025 are unlike any in previous decades. Volatility has become a constant companion, inflationary cycles are unpredictable, and traditional valuation models often fail to capture the momentum behind emerging sectors. Investors are forced to adapt, searching for assets that combine stability, transparency, and long-term growth potential.

In this landscape, the question is no longer what to buy, but how to identify quality. The criteria for defining “high-quality assets” have evolved — it now encompasses not just performance, but also resilience, governance, and data-backed fundamentals.

Michael Hartnett, who has spent years studying global capital flows and behavioral finance, believes that technology can finally bridge the gap between complexity and clarity. “Investors are not struggling from a lack of data,” Hartnett explains. “They are struggling because there’s too much of it. The key is to filter information through intelligent systems that can recognize real value where others see only volatility.”

Introducing DSLAI and DLMSPVAI — Redefining Analytical Precision

At the core of DLM SPV LLC’s approach are DSLAI (Dynamic Smart Learning AI) and DLMSPVAI, two interconnected analytical engines that combine data modeling, sentiment analysis, and structural pattern verification.

DSLAI operates as a machine learning backbone that continuously studies correlations between macroeconomic indicators, corporate disclosures, and behavioral market signals. It is designed to understand not only what moves markets but why. By decoding hidden relationships between liquidity trends, risk tolerance, and capital rotation, DSLAI can flag potential opportunities long before they reach mainstream attention.

Complementing this is DLMSPVAI, an evolved model that applies predictive analytics to simulate multiple market scenarios. Rather than focusing on short-term price changes, DLMSPVAI measures sustainability — identifying assets capable of withstanding cyclical downturns and technological disruptions.

Together, the two systems represent DLM SPV’s philosophy: empowering investors through knowledge, not speculation.

The DLM SPV Framework: Where AI Meets Human Insight

Technology alone cannot define a good investment. While DSLAI and DLMSPVAI automate large-scale data processing, human interpretation remains critical. Michael Hartnett emphasizes that “data is only as good as the discipline guiding it.”

Under the DLMSPV (Dynamic Learning Market Smart Portfolio Validation) model, DLM SPV LLC combines algorithmic forecasting with human review. Analysts trained under the DLM framework evaluate data through multiple dimensions: sector relevance, liquidity depth, management quality, and regulatory transparency.

This hybrid approach ensures that the AI’s findings are grounded in real-world reasoning. It is not merely a matter of numbers but of narrative — understanding how global events, leadership decisions, and consumer sentiment collectively shape an asset’s trajectory.

Redefining What “Quality” Means in a Fragmented Market

According to Hartnett, the term “quality” has been misinterpreted for too long. “Investors often equate quality with brand recognition or market capitalization,” he notes. “But true quality is defined by adaptability — the ability of an asset or a company to generate consistent value across different economic cycles.”

Through DSLAI and DLMSPVAI, DLM SPV identifies these traits by analyzing the behavioral consistency of assets over time. For example:

How do institutional holdings shift during uncertainty?

How resilient are earnings against interest rate changes?

Does the underlying business model scale with technological transformation?

These questions go beyond price movements, capturing a deeper picture of structural strength.

The Role of AI in Democratizing Market Access

For decades, institutional investors held an advantage in accessing complex analytical tools and datasets. Retail and mid-level investors often relied on fragmented sources of information. DLM SPV LLC aims to close this gap by leveraging AI frameworks like DSLAI to create transparent analytical access for all investors — whether they are managing a personal portfolio or institutional capital.

Through its platform at https://dlmqy.com, DLM SPV integrates interactive dashboards and algorithmic insights that translate raw financial data into actionable intelligence. Users can visualize correlations, assess market health, and identify early signals of structural change.

This is not about predicting markets with absolute certainty — an impossible task — but about increasing the probability of success through better-informed decisions.

Michael Hartnett’s Philosophy: From Teaching to Empowering

Michael Hartnett’s contribution to DLM SPV extends beyond technical systems. A long-time educator and analyst, he believes that investment literacy is as important as access to capital.

“The most valuable asset is understanding,” he says. “Technology amplifies knowledge, but it cannot replace judgment. That’s why DLM SPV’s mission is not only to deliver tools but to cultivate decision-makers.”

To this end, the company has integrated education modules within its ecosystem — allowing users to learn how DSLAI and DLMSPVAI interpret data, rather than simply accepting recommendations. The goal is transparency: empowering investors to trust their reasoning as much as the algorithm.

The Rise of Data-Conscious Investing

The success of DLM SPV’s approach reflects a broader shift across the investment world. Traditional asset managers are embracing AI not as a novelty but as a necessity. As markets become more interconnected, the ability to process information at scale is essential.

DLM SPV’s innovation lies in how it applies AI to human behavior, not just numbers. By modeling collective decision patterns, DSLAI identifies when market sentiment diverges from fundamentals — often a precursor to correction or opportunity.

This perspective is especially valuable in the age of behavioral volatility, where sentiment, social trends, and algorithmic trading intersect.

Balancing Automation and Accountability

One of the recurring challenges in financial AI systems is accountability — ensuring that automated insights remain ethical, unbiased, and verifiable.

DLM SPV LLC has developed DLMSPVAI’s validation layer, which requires human confirmation for all AI-generated signals before portfolio action. This safeguards against overreliance on algorithmic bias and reinforces a culture of professional accountability.

Hartnett explains, “Technology should not replace trust — it should earn it. The best systems are those that make investors more aware, not more dependent.”

From Analysis to Action: Turning Knowledge into Portfolio Strength

Identifying a quality asset is only the beginning. What distinguishes DLM SPV’s framework is how it translates intelligence into structured portfolio validation.

Through the DLMSPV model, assets are evaluated not only for performance but for interconnectivity — how each position strengthens or diversifies the overall portfolio. The AI’s ability to detect unseen correlations allows investors to reduce exposure to systemic risk while optimizing growth potential.

This methodology has gained attention among institutional advisors seeking to merge AI analytics with responsible portfolio construction.

Looking Ahead: Building a Smarter Financial Future

As global markets transition into an era dominated by digital assets, tokenization, and real-world asset integration, DLM SPV LLC is positioning itself as a thought leader in intelligent asset discovery.

The company’s vision extends beyond short-term market relevance. Its goal is to redefine how investors interact with information — transforming data into comprehension, and comprehension into confidence.

Michael Hartnett summarizes this mission succinctly:

“The future of investing is not about prediction; it’s about perception. Those who understand the structure of change will always find opportunity within it.”

Conclusion

In a world where data is abundant but clarity is rare, DLM SPV LLC and Michael Hartnett are offering a bridge — connecting technology, transparency, and education. Through systems like DSLAI, DLMSPV, and DLMSPVAI, the company is building more than analytical tools; it is cultivating a philosophy of informed, intelligent investing.

Investors seeking to learn more about DLM SPV’s framework or explore its analytical systems can visit https://dlmqy.com or contact services@dlmqys.vip for further information.

As financial markets continue to evolve, one truth remains: the most powerful investment is not in assets themselves, but in the knowledge that helps define them.

Media Contact

Organization: DLM SPV LLC

Contact Person: Michael Hartnett

Website: https://dlmqy.com/

Email:
services@dlmqys.vip

Country:Armenia

Release id:35056

The post DLMSPV LLC and Michael Hartnett Helping Global Investors Identify Quality Assets through DSLAI and DLMSPVAI Frameworks appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Forex Expo Dubai Wins Guinness World Records™ with 20,021 Visitors

Published

on

Dubai, UAE, 8th October 2025, ZEX PR WIRE, By winning the Guinness World Records™ for “Largest attendance at a Forex Event” & “Most Exhibitors at a Forex Event”, the 8th edition of Forex Expo Dubai this year is announced as the world’s largest event in forex & online trading industry.

The historical event, Forex Expo took place in Dubai World Trade Center (DWTC) on 6-7 October 2025 with 262 Exhibiting companies and 147 Industry Experts as speaker from over 100 Countries making the world’s largest exhibition and conference in online trading industry.

The record was achieved during Forex Expo Dubai, as footfall reached 20,021 visitors that comprises of 16,994 online traders/investors, 671 IBs/Affiliates  and 2,356 business professionals, reinforcing Dubai’s position as the financial powerhouse of the Middle East.

Early this Monday, Dubai Police noted traffic congestion around the Dubai World Trade Centre (DWTC) as large crowds arrived for Forex Expo and two other concurrent events, highlighting the venue’s growing role as a hub for international gatherings.

Niyaz Mohamed from Forex Expo Team added “This achievement goes beyond numbers — it reflects Forex Expo Dubai’s position as a global platform for innovation and finance. We’re honoured to set new benchmarks for the forex industry.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Vitals Vault Brings $4,500 Longevity Clinic Testing to the Public for Just $399

Published

on

100+ biomarkers, AI-powered insights, and early detection are now accessible to everyone.

Seattle, WA, USA– Vitals Vault, a next-generation health optimization platform, is transforming how individuals take control of their health. By offering access to over 100 precision biomarker tests, AI-driven insights, and clinician-reviewed reports, Vitals Vault is bridging the gap between expensive longevity clinics and the limited scope of traditional annual physicals.

Accessible Pricing with Launch Special

Individually, these tests cost over $1,700 if purchased separately. The full Vitals Vault comprehensive panel regularly retails for $599, already a fraction of the price of longevity clinics that charge $4,000 -$5,000. For its limited launch, Vitals Vault is making this same full-body health scan available for just $399 – bringing advanced longevity testing within reach for everyone.

The Number That Matters More Than Your Birthday

Beyond testing for disease risk, Vitals Vault measures how fast your body is actually aging. Using PhenoAge, an advanced algorithm built from key blood markers, the platform calculates your biological age – a true reflection of cellular health, resilience, and longevity potential. Unlike your birthdate, this measure shows whether you’re aging faster or slower than expected. Armed with this insight, individuals can take targeted, science-based steps proven to slow – and in some cases reverse – the pace of aging.

A New Era in Preventive Health

For decades, the standard medical model has focused on detecting sickness rather than preventing it. Annual physicals typically measure only 12–20 markers, leaving fatigue, hidden inflammation, and silent heart risk unnoticed until it’s too late.

Meanwhile, longevity clinics charge as much as $4,500 for advanced testing, placing optimal health out of reach for most people.

Vitals Vault challenges this system by making comprehensive testing and actionable health optimization accessible and affordable. With CLIA-certified labs, HIPAA-compliant data protection, and HSA/FSA eligibility, the platform delivers the same scientific rigor as elite clinics at a fraction of the cost.

What’s Included: 112+ Biomarkers That Go Far Beyond a Physical

Instead of the 12–20 basic labs typically offered at a doctor’s office, Vitals Vault provides a complete map of health with over 100+ tests across every major system. 

Some of the most critical include:

  • ApoB – The most powerful predictor of heart attack and stroke risk, yet rarely included in standard physicals.
  • Lipoprotein(a) – A hidden genetic risk factor most doctors never check, strongly linked to early heart attacks and strokes—even when cholesterol appears normal.
  • hs-CRP – A key inflammation marker not only driving silent cardiovascular disease, but also linked to accelerated biological aging and predicting future risk of heart attack years before symptoms appear.
  • Homocysteine – Elevated levels are linked not only to cognitive decline, stroke, and Alzheimer’s, but also to accelerated brain shrinkage—studies show lowering homocysteine with B-vitamins can slow brain atrophy by over 30% and preserve memory.
  • Advanced cholesterol & triglycerides – Go beyond ‘total cholesterol’ to reveal hidden particle patterns and lipid risks that standard panels miss.
  • Fasting insulin + HOMA-IR – Detect hidden insulin resistance years before glucose or A1C changes, offering an early warning for diabetes and metabolic disease.
  • Hemoglobin A1C – The gold standard for tracking long-term blood sugar control and uncovering hidden diabetes risk.
  • Full thyroid panel (TSH, Free T4, Free T3, Reverse T3, antibodies) – The most comprehensive thyroid check – revealing hidden imbalances that drive fatigue, stubborn weight gain, mood shifts, and hair loss that a standard TSH test alone often misses.
  • Ferritin & Iron – Reveal hidden anemia or iron overload—two underdiagnosed causes of constant exhaustion, brain fog, and poor performance.
  • Vitamin D, B12, Folate – Essential nutrient trio uncovering deficiencies that quietly drive fatigue, low mood, and weakened immunity.
  • Testosterone (free & total) – The master vitality hormone influencing energy, strength, mood, drive, and libido in both men and women – often overlooked outside men’s health.
  • Estradiol, Progesterone, FSH, LH – Core reproductive hormones regulating fertility, hormonal balance, mood, and life-stage transitions in both sexes, not just women.
  • Cortisol & DHEA-S – stress and resilience markers influencing sleep, recovery, and aging.
  • Liver enzymes (ALT, AST, GGT) – detect alcohol, medication, or diet-related strain.
  • Kidney markers (Creatinine, eGFR, Albumin/Creatinine Ratio) – uncover early kidney warning signs most doctors miss.

This depth of testing is designed to uncover imbalances years before they manifest as disease, empowering users to intervene early and live longer, healthier lives.

Personalized AI-Driven Health Reports

Every Vitals Vault client receives more than just raw lab data. Results are reviewed by advanced AI systems that compare biomarkers against optimal, not just “normal”, ranges. The platform delivers a personalized Functional Health Report that includes:

  • Food and supplement guidance tailored to biomarker results
  • Lifestyle recommendations for sleep, stress, and exercise
  • Urgent result flagging for immediate attention
  • A biological age (PhenoAge) calculation to measure true aging beyond the calendar

Health History Integration

Vitals Vault also empowers clients to upload past lab reports from other providers, creating a continuous health timeline. Instead of treating every test as an isolated snapshot, the platform stitches data together – revealing long-term trends, hidden patterns, and whether interventions are truly working. This longitudinal view, once only available at elite concierge clinics, is now accessible to everyone. Clients can securely track their progress, spot subtle changes early, and share evolving insights with their physicians.

Trusted, Affordable, and Transparent

Vitals Vault operates with a one-time $399 purchase; no subscriptions, no hidden fees, and no automatic renewals. Customers schedule their tests at one of 2,000+ Quest Diagnostics locations nationwide, receive results within 7 days, and gain access to insights typically reserved for the wealthy.

The company also offers a 60-day money-back guarantee, underscoring its confidence in providing measurable value.

Why Vitals Vault Matters Now

With 74% of adults reporting exhaustion and nearly all lacking clarity on the cause, Vitals Vault positions itself as the clear alternative to “bare minimum” healthcare. Instead of waiting years for conditions like pre-diabetes or hormone imbalances to surface, individuals can now identify risks early, act on them, and reclaim control of their health journey.

For more information, visit www.vitalsvault.com.

About Vitals Vault

Vitals Vault, Inc. is a Seattle-based health optimization company committed to making comprehensive, science-driven health insights accessible to everyone. Through partnerships with leading labs and the integration of AI technology, Vitals Vault delivers precision biomarker analysis, personalized action plans, and unparalleled value. The platform empowers individuals to take charge of their health, longevity, and performance, without the inflated costs of concierge medicine.

For updates follow Vitals Vault on LinkedIn: https://www.linkedin.com/company/vitals-vault/

Media Contact

Company Name: Vitals Vault, Inc.

Contact Person: Media Relations

Email: team@vitalsvault.com

Website: https://www.vitalsvault.com/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST